Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment

Porter JB 1 , El-Alfy M 2 , Viprakasit V 3 , Giraudier S 4 , Chan LL 5 , Lai Y 6 Show all authors , El-Ali A 7 , Han J 8 , Cappellini MD 9

Affiliations 

  • 1 University College London, London, UK
  • 2 Ain Shams University, Cairo, Egypt
  • 3 Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 4 Hôpital Henri Mondor, Créteil, France
  • 5 University Malaya Medical Centre, Kuala Lumpur, Malaysia
  • 6 The First Affiliated Hospital of Guangxi Medical University, Nanning, China
  • 7 Novartis Pharma AG, Basel, Switzerland
  • 8 Novartis Pharmaceuticals, East Hanover, NJ, USA
  • 9 Policlinico Foundation IRCCS, Università di Milano, Milan, Italy
Eur. J. Haematol., 2016 Jan;96(1):19-26.
PMID: 25691036 DOI: 10.1111/ejh.12540

Abstract

Plasma markers in addition to serum ferritin (SF) may be useful for the assessment of iron overload; however, predictive utility may differ depending on underlying, transfusion-dependent, anemias.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications